

Table of Contents

- OVERVIEW
 - Catalyst
 - Summary
- EXECUTIVE SUMMARY
 - Strategic scoping and focus
 - Datamonitor insight into the cancer therapies market
 - Related reports
 - Upcoming related reports
- MARKET DEFINITION
 - Market definition for this report
 - Antihormonal therapies by ATC class
 - Cytotoxic therapies by ATC class
 - Targeted therapies and immunotherapies by ATC class
- MARKET OVERVIEW
 - Cancer therapy brands included in this report
 - Seven major market assessment
 - Current and future market overview
 - Opportunities and threats
 - US market assessment
 - Current and future market overview
 - Opportunities and threats
 - Japan market assessment
 - Current and future market overview
 - Opportunities and threats
 - Five major EU market assessment

- Current and future market overview
 - Opportunities and threats
 - France
 - Current and future market assessment
 - Germany
 - Current and future market assessment
 - Italy
 - Current and future market assessment
 - Spain
 - Current and future market assessment
 - UK
 - Current and future market assessment
 - Rest of the World snapshot
 - Current market assessment
 - Opportunities and threats
- BRAND DYNAMICS
 - Overview of competitive landscape
 - (Untitled sub-section)
 - Avastin (bevacizumab; Roche/Chugai)
 - Drug profile
 - Product positioning
 - SWOT analysis
 - Brand forecast to 2019

- Rituxan/MabThera (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo)
 - Drug profile
 - Product positioning
 - SWOT analysis
 - Brand forecast to 2019
- Herceptin (trastuzumab; Roche/Chugai)
 - Drug profile
 - Product positioning
 - SWOT analysis
 - Brand forecast to 2019
- Gleevec/Glivec (imatinib; Novartis)
 - Drug profile
 - Product positioning
 - SWOT analysis
 - Brand forecast to 2019
- Taxotere (docetaxel; Sanofi-Aventis)
 - Drug profile
 - Product positioning
 - SWOT analysis
 - Brand forecast to 2019
- Revlimid (lenalidomide; Celgene)
 - Drug profile
 - Product positioning

- SWOT analysis
- Brand forecast to 2019
- KEY DEVELOPERS
 - Strategic overview
 - Trends in corporate strategy
 - Partnerships in the cancer therapies market offer considerable benefits for smaller companies and Big Pharma alike
 - The high-risk nature of indication expansion in broad patient populations has prompted a switch in strategy for developers of targeted therapies and immunotherapies
 - Roche
 - Corporate strategy
 - Cancer therapies portfolio assessment
 - Sanofi-Aventis
 - Corporate strategy
 - Cancer therapies portfolio assessment
 - Novartis
 - Corporate strategy
 - Cancer therapies portfolio assessment
 - AstraZeneca
 - Corporate strategy
 - Cancer therapies portfolio assessment
 - Eli Lilly
 - Corporate strategy
 - Cancer therapies portfolio assessment

- BIBLIOGRAPHY
 - Journal papers
 - Websites
 - Datamonitor reports
 - Other

- APPENDIX A – MARKET ASSUMPTIONS
 - Forecasting assumptions
 - Patent expiries
 - Data definitions, limitations and assumptions
 - Standard units
 - Country group definitions
 - Forecast methodology
 - Derivation of sales forecasts and pricing trends
 - Exchange rates
 - Report methodology

- APPENDIX B

- TABLES
 - Table: Definition of the cancer market, 2010
 - Table: Drugs included in the Top 20 cancer therapy brands, 2009 and 2019
 - Table: Sales and growth of cancer therapy drug classes in the seven major markets, 2009–2019
 - Table: Key events impacting the cancer therapies market in the seven major markets, 2010–19
 - Table: Sales of the Top 20 cancer therapy brands in the seven major markets, 2009
 - Table: Forecast sales of the Top 20 cancer therapy brands in 2019 in the seven major markets (\$m), 2009–2019
 - Table: Summary of opportunities and threats that will impact the cancer therapy market across the seven major markets, 2009–2019
 - Table: Sales and growth of cancer therapy drug classes in the US, 2009–2019

- Table: Sales of the Top 20 cancer therapy brands in the US, 2009
- Table: Forecast sales of the Top 20 cancer therapy brands in 2019 in the US (\$m), 2009–2019
- Table: Summary of opportunities and threats to impact the cancer therapy market in the US, 2009–2019
- Table: Sales and growth of cancer therapy drug classes in Japan, 2009–2019
- Table: Sales of the Top 20 cancer therapy brands in Japan, 2009
- Table: Forecast sales of the Top 20 cancer therapy brands in 2019 in Japan (\$m), 2009–2019
- Table: Summary of opportunities and threats to impact the cancer therapy market in Japan, 2009–2019
- Table: Sales and growth of cancer therapy drug classes in the five major EU markets, 2009–2019
- Table: Sales of the Top 20 cancer therapy brands in the five major EU markets, 2009
- Table: Forecast sales of the Top 20 cancer therapy brands in 2019 in five major EU markets (\$m), 2009–2019
- Table: Summary of opportunities and threats to impact the cancer therapy market in the five major EU markets, 2009–2019
- Table: Risk-sharing agreements between NICE and selected pharma companies in the UK, 2009–2010
- Table: Sales and growth of cancer therapy drug classes in France, 2009–2019
- Table: Sales of the Top 20 cancer therapy brands in France, 2009
- Table: Forecast sales of the Top 20 cancer therapy brands in 2019 in France (\$m), 2009–2019
- Table: Sales and growth of cancer therapy drug classes in Germany, 2009–2019
- Table: Sales of the Top 20 cancer therapy brands in Germany, 2009
- Table: Forecast sales of the Top 20 cancer therapy brands in 2019 in Germany (\$m), 2009–2019
- Table: Sales and growth of cancer therapy drug classes in Italy, 2009–2019
- Table: Sales of the Top 20 cancer therapy brands in Italy, 2009
- Table: Forecast sales of the Top 20 cancer therapy brands in 2019 in Italy (\$m), 2009–2019
- Table: Sales and growth of cancer therapy drug classes in Spain, 2009–2019
- Table: Sales of the Top 20 cancer therapy brands in Spain, 2009
- Table: Forecast sales of the Top 20 cancer therapy brands in 2019 in Spain (\$m), 2009–2019
- Table: Sales and growth of cancer therapy drug classes in the UK, 2009–2019
- Table: Sales of the Top 20 cancer therapy brands in the UK, 2009

- Table: Forecast sales of the Top 20 cancer therapy brands in 2019 in the UK (\$m), 2009–2019
- Table: Comparison of the cancer therapy drug classes by sales in the US, Japan, the five major EU markets and the Rest of the World in 2009 (\$m), 2009
- Table: Branded cancer therapy sales in the seven major markets, 2009 and 2019
- Table: Avastin (bevacizumab; Roche/Chugai) – drug profile, 2010
- Table: Factors impacting revenues of Avastin, 2010–19
- Table: Rituxan/MabThera (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo) – drug profile, 2010
- Table: Factors impacting revenues of Rituxan/MabThera, 2010–19
- Table: Herceptin (trastuzumab; Roche/Chugai) – drug profile, 2010
- Table: Factors impacting revenues of Herceptin, 2010–19
- Table: Gleevec/Glivec (imatinib; Novartis) – drug profile, 2010
- Table: Factors impacting revenues of Gleevec/Glivec, 2010–19
- Table: Taxotere (docetaxel) – drug profile, 2010
- Table: Impacting factors on the revenues of Taxotere, 2009–2019
- Table: Revlimid (lenalidomide; Celgene) – drug profile, 2010
- Table: Factors impacting revenues of Revlimid, 2010–19
- Table: Leading companies in the cancer targeted therapies and immunotherapies market by sales in the seven major markets (\$m), 2009–2019
- Table: Assessment of Roche’s cancer therapies portfolio, 2010
- Table: Assessment of Sanofi-Aventis’s cancer therapy portfolio, 2010
- Table: Assessment of Novartis’s cancer therapies portfolio, 2010
- Table: Assessment of AstraZeneca’s cancer therapies portfolio, 2010
- Table: Assessment of Eli Lilly’s cancer therapies portfolio, 2010
- Table: Regional launch dates for new cancer therapies in the seven major markets, 2010–19
- Table: Patent expiry dates for the approved cancer therapies in the seven major pharmaceutical markets, 2010–19

- FIGURES

- Figure: Cancer therapy sales (\$m) in the seven major markets, 2009–2019
- Figure: Comparison of branded versus generic value of cancer therapies in the seven major pharmaceutical markets (\$m), 2009 and 2019
- Figure: Cancer therapy sales (\$m) by country in the seven major markets, 2009–2019
- Figure: Cancer therapy sales (\$m) by class in the seven major markets, 2009–2019
- Figure: Sales and market share of the leading 10 cancer therapy brands in the seven major markets, 2009 and 2019
- Figure: Seven major market population aged 60 and over, 2000–2050
- Figure: Global therapy sales (\$m), 2009–2015

- Figure: Cancer therapy sales (\$m) by class in the US, 2009–2019
- Figure: Cancer therapy sales (\$m) by class in Japan, 2009–2019
- Figure: Cancer therapy sales (\$m) by class in the five major EU markets, 2009–2019
- Figure: Cancer therapy sales (\$m) by class in France, 2009–2019
- Figure: Cancer therapy sales (\$m) by class in Germany, 2009–2019
- Figure: Cancer therapy sales (\$m) by class in Italy, 2009–2019
- Figure: Cancer therapy sales (\$m) by class in Spain, 2009–2019
- Figure: Cancer therapy sales (\$m) by class in the UK, 2009–2019
- Figure: Rest of the World versus seven major market sales split for sales of cancer therapies (\$m), 2009
- Figure: Avastin – SWOT analysis in cancer, 2010
- Figure: Avastin forecast sales by country in the seven major markets (\$m), 2009–2019
- Figure: Rituxan/MabThera – SWOT analysis in cancer, 2010
- Figure: Rituxan/MabThera forecast sales by country in the seven major markets (\$m), 2009–2019
- Figure: Herceptin – SWOT analysis in cancer, 2010
- Figure: Herceptin forecast sales by country in the seven major markets (\$m), 2009–2019
- Figure: Gleevec/Glivec – SWOT analysis in cancer, 2010
- Figure: Gleevec/Glivec forecast sales by country in the seven major markets (\$m), 2009–2019
- Figure: Taxotere — SWOT analysis in cancer, 2010
- Figure: Taxotere forecast sales by country in the seven major markets (\$m), 2009–2019
- Figure: Revlimid – SWOT analysis in cancer, 2010
- Figure: Revlimid forecast sales by country in the seven major markets (\$m), 2009–2019
- Figure: Methodology for forecasting price to remove impact of currency fluctuations on future trend